<div id="readability-page-1"><p>Wedbush analyst David Nierengarten maintained a Buy rating on Disc Medicine on December 8 and set a price target of $110.00. The company’s shares closed yesterday at $92.24.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Nierengarten covers the Healthcare sector, focusing on stocks such as AnaptysBio, Argenx Se, and Oric Pharmaceuticals. According to TipRanks, Nierengarten has an average return of <span>19.5%</span> and a 50.10% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $118.55 average price target, which is a 28.52% upside from current levels. In a report released on December 9, H.C. Wainwright also maintained a Buy rating on the stock with a $118.00 price target.</p></div>

IRON

<p>Wedbush analyst David Nierengarten maintained a Buy rating on Disc Medicine with a $110 price target. The stock closed at $92.24, and analysts suggest a Strong Buy consensus with a $118.55 average price target, indicating a 28.52% upside. H.C. Wainwright also maintained a Buy rating with a $118 target.</p>

Disc Medicine (IRON) Receives a Buy from Wedbush